Cell Therapy News Volume 23.13 | Apr 25 2022

    0
    75







    2022-05-25 | CTN 13.13


    Cell Therapy News by STEMCELL Technologies
    Vol. 13.13 – 25 April, 2022
    TOP STORY

    Non-Cleavable Hinge Enhances Avidity and Expansion of CAR-T Cells for Acute Myeloid Leukemia

    Investigators started with a CD27-based CAR to target CD70 in acute myeloid leukemia, and they found modest efficacy in vivo, consistent with prior reports.
    [Cancer Cell]

    AbstractGraphical Abstract
    Enter your best cell image by April 28 for a chance to win!
    PUBLICATIONSRanked by the impact factor of the journal

    Allogeneic Double-Negative CAR-T Cells Inhibit Tumor Growth without Off-Tumor Toxicities

    To overcome the challenges faced with CAR-T cells using donor-derived conventional CD4+ or CD8+ T cells, scientists evaluated the feasibility, safety, and efficacy of using healthy donor–derived allogeneic double-negative T cells as a CAR-T cell therapy platform.
    [Science Immunology]

    Abstract

    Differential Effects of Macrophage Subtypes on SARS-CoV-2 Infection in a Human Pluripotent Stem Cell-Derived Model

    Researchers established a lung and macrophage co-culture system derived from human pluripotent stem cells, modeling the host-pathogen interaction in SARS-CoV-2 infection.
    [Nature Communications]

    Full Article

    GM-CSF Disruption in CART Cells Modulates T Cell Activation and Enhances CART Cell Anti-Tumor Activity

    Scientists studied the direct impact of granulocyte-macrophage colony-stimulating factor (GM-CSF) disruption during the production of CD19-directed CART cells on their effector functions, independent of GM-CSF modulation of myeloid cells.
    [Leukemia]

    Abstract

    Chimeric Anti-GPC3 sFv-CD3ε Receptor Modified T Cells with IL7 Co-Expression for the Treatment of Solid Tumors

    To improve the efficacy and safety of glypican-3 (GPC3)-targeted adoptive cell therapies, T cells were modified with anti-GPC3 single-chain fragment variable (sFv) linked to CD3ε, which could be incorporated into the entire TCR/CD3 complex to form chimeric sFv-CD3ε receptor (sFv-ε).
    [Molecular Therapy Oncolytics]

    AbstractFull ArticleGraphical Abstract

    Chimeric Antigen Receptor Clustering via Cysteines Enhances T Cell Efficacy against Tumor

    The authors generated CARCys-T cells using a 4-1BB-derived hinge region including 11 cysteines residues. The cysteines in the hinge were found to facilitate CARCys clustering upon antigen stimulation and promote the antitumor activity of CAR-T cells.
    [Cancer Immunology Immunotherapy]

    Abstract

    Human Embryonic Stem Cell-Derived Dopaminergic Grafts Alleviate L-DOPA Induced Dyskinesia

    Investigators attempted to determine whether L-DOPA impacted the survival and functional recovery following grafting of human embryonic stem cell-derived dopaminergic neurons.
    [Journal of Parkinsons Disease]

    Abstract

    Human Amniotic Fluid Stem Cells Can Alleviate Detrusor Dysfunction Caused by Bladder Outlet Obstruction in Rats

    The authors examined whether bladder detrusor dysfunction due to partial bladder outlet obstruction could be improved after the treatment of human amniotic fluid stem cells.
    [Scientific Reports]

    Full Article

    Various Detailed Characteristics of a New Enhanced Neurotrophic Factor Secreting Rat Derived Bone Marrow Mesenchymal Stem Cells and Its Preliminary Application in Rat Models of Ischemic Stroke

    Researchers established some important characteristics that can be used to distinguish between MSC-NTF and MSCs: different multi-factor secretion ability and secretion characteristics, immunogenicity, three-line differentiation ability, stemness, etc.
    [Experimental Cell Research]

    Abstract
    ON1091CS-AAI-2022-Immunology-Podcast-728x90-1
    REVIEWS

    Biological and Molecular Factors Predicting Response to Adoptive Cell Therapies in Cancer

    It is crucial to discover and develop reliable and robust biomarkers to specifically and sensitively pinpoint the patients that will benefit the most from adoptive cell therapy, as well as those that are at higher risk of developing potentially serious toxicities.
    [JNCI-Journal of the National Cancer institute]

    Abstract

    Mesenchymal Stem Cell Therapy for Focal Epilepsy: A Systematic Review of Preclinical Models and Clinical Studies

    Thus far, therapy with mesenchymal stem cells appears to be safe for use in humans, as no severe adverse events directly related to the therapy were reported.
    [Epilepsia]

    Abstract
    INDUSTRY AND POLICY NEWS

    Porton Advanced and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Cell Therapy Development for Solid Tumors

    Suzhou Porton Advanced Solutions Ltd. and Guizhou Sinorda Biomedicine Co. Ltd announced a long-term strategic partnership in cell and gene therapy R&D and platform development.
    [Suzhou Porton Advanced Solutions Ltd. (Businesswire, Inc.)]

    Press Release

    Mustang Bio Announces Updated Interim Phase I/II Data for MB-106, CD20-Targeted CAR T Therapy, in Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

    Mustang Bio, Inc. announced updated interim data from the ongoing Phase I/II clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B cell non-Hodgkin lymphomas and chronic lymphocytic leukemia
    [Mustang Bio]

    Press Release

    FEATURED EVENT

    Translational Immunometabolism

    June 26 – 28, 2022
    Basel, Switzerland

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Position – 3D Bioprinting

    IMPACT – Santiago, Chile

    Scientist/Lead Researcher – Cell Therapy for Leukemias

    St. Jude Children’s Research Hospital – Memphis, Tennessee, United States

    Technician – Cell Culture

    Novo Nordisk – Fremont, California, United States

    Postdoctoral Fellow Position – Translational Research

    Stanford University – Stanford, California, United States

    Science Writer – Blood Cancer

    Fred Hutchinson Cancer Research Center – Seattle, Washington, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cell Therapy News Twitter